Basit öğe kaydını göster

dc.contributor.authorDerle, Eda
dc.contributor.authorAkinci, Tuba
dc.contributor.authorKibaroglu, Seda
dc.contributor.authorHarman, Ali
dc.contributor.authorKural, Feride
dc.contributor.authorCinar, Pinar
dc.contributor.authorKilinc, Munire
dc.contributor.authorAkay, Hakki T.
dc.contributor.authorCan, Ufuk
dc.contributor.authorBenli, Ulku S.
dc.date.accessioned2019-06-18T10:31:57Z
dc.date.available2019-06-18T10:31:57Z
dc.date.issued2016
dc.identifier.issn1319-6138
dc.identifier.urihttp://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC5224429&blobtype=pdf
dc.identifier.urihttp://hdl.handle.net/11727/3592
dc.description.abstractObjective: To review our results of carotid artery stenting (CAS) and carotid endarterectomy (CEA). Methods: We evaluated the medical records of patients undergoing carotid artery revascularization procedure, between 2001 and 2013 in Baskent University Hospital, Ankara, Turkey. Carotid artery stenting or CEA procedures were performed in patients with asymptomatic carotid stenosis (=70%) or symptomatic stenosis (=50%). Demographic data, procedural details, and clinical outcomes were recorded. Primary outcome measures were in 30-day stroke/transient ischemic attacks (TIA)/amaurosis fugax or death. Secondary outcome measures were nerve injury, bleeding complications, length of stay in hospital, stroke, restenosis (ICA patency), and all-cause death during long-term follow-up. Results: One hundred ninety-four CEA and 115 CAS procedures were performed for symptomatic and/or asymptomatic carotid artery stenosis. There is no significant differences 30-day mortality and neurologic morbidity between CAS (13%) and CEA procedures (7.7%). Length of stay in hospital were significantly longer in CEA group (p=0.001). In the post-procedural follow up, only in symptomatic patients, restenosis rate was higher in the CEA group (p=.045). The other endpoints did not differ significantly. Conclusions: Endovascular stent treatment of carotid artery atherosclerotic disease is an alternative for vascular surgery, especially for patients that are high risk for standard CEA. The increasing experience, development of cerebral protection systems and new treatment protocols increases CAS feasibility.en_US
dc.language.isoengen_US
dc.relation.isversionof10.17712/nsj.2016.4.20160079en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectREVASCULARIZATION ENDARTERECTOMYen_US
dc.subjectSTENOSISen_US
dc.subjectTRİALen_US
dc.subjectCRESTen_US
dc.subjectANGIOPLASTYen_US
dc.titleClinical results of carotid artery stenting versus carotid endarterectomyen_US
dc.typeeditorialen_US
dc.relation.journalNEUROSCIENCESen_US
dc.identifier.volume21en_US
dc.identifier.issue4en_US
dc.identifier.startpage319en_US
dc.identifier.endpage325en_US
dc.identifier.wos000393113900004en_US
dc.identifier.scopus2-s2.0-84992145841en_US
dc.contributor.pubmedID27744460en_US
dc.contributor.orcID0000-0002-7386-7110en_US
dc.contributor.orcID0000-0002-4226-4034en_US
dc.contributor.orcID0000-0002-9975-3170en_US
dc.contributor.orcID0000-0003-2122-1016en_US
dc.contributor.orcID0000-0002-3964-268Xen_US
dc.contributor.orcID0000-0001-8689-417Xen_US
dc.contributor.researcherIDAAI-8830-2021en_US
dc.contributor.researcherIDAAJ-2956-2021en_US
dc.contributor.researcherIDK-9824-2013en_US
dc.contributor.researcherIDAAL-9808-2021en_US
dc.contributor.researcherIDAAJ-4403-2021en_US
dc.contributor.researcherIDAAJ-2999-2021en_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster